Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.56 [0.14, 2.22]1 study · 95 participantsLow